ABSTRACT
ABSTRACT Each year, more than one-half million women worldwide are diagnosed with cervical cancer. A key to improved treatment results for women with advanced-stage disease is the planned inclusion of inhibitors of ribonucleotide reductase (RNR). Although gaps remain in our knowledge of how best to inhibit RNR during radiochemotherapy treatment of this disease, as yet no other treatment combination can bring the clinical benet that RNR inhibition-based radiochemotherapy delivers. This chapter discusses RNR structure, mechanism, and pharmacologic inhibition as it pertains to cervical cancer cell radiosensitivity.
